North America Non Invasive Colon Cancer Screening Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
North America Non Invasive Colon Cancer Screening Market Analysis — Presence
Geographical Analysis
Click countries to exploreCountry Analysis
North America Non Invasive Colon Cancer Screening Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| North America Non Invasive Colon Cancer Screening Total | xxxx | xxxx | xxxx | 2.9% |
| United States | xxxx | xxxx | xxxx | xxxx |
| Canada | xxxx | xxxx | xxxx | xxxx |
| Mexico | xxxx | xxxx | xxxx | xxxx |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Non Invasive Colon Cancer Screening Market
The competitive landscape of the Non-Invasive Colon Cancer Screening Market is characterized by intense rivalry among players striving to innovate and expand their product portfolios. Key strategies include technological advancements, strategic partnerships, and market expansion efforts to gain a competitive edge in this dynamic and rapidly evolving market segment.
Non Invasive Colon Cancer Screening Industry News
In March 2021, Olympus disclosed that the FDA had granted 510(k) clearance to Narrow Band Imaging for evaluating the neoplastic potential of colorectal polyps. Utilizing the NBI International Colorectal Endoscopic (NICE) classification during screening colonoscopies enables physicians to confidently predict the histology of diminutive polyps (5mm or smaller). Implementation of NBI serves as a valuable decision-making support tool, offering benefits to patients and healthcare systems alike by facilitating informed medical assessments during colorectal examinations.(Source:https://medical.olympusamerica.com/articles/fda-clears-olympus%E2%80%99-narrow-band-imaging%C2%AE-nbi-use-assessing-colonic-lesions)
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Company 1 | ••• | ••• | ••• | ••• |
| Company 2 | ••• | ••• | ••• | ••• |
| Company 3 | ••• | ••• | ••• | ••• |
| Company 4 | ••• | ••• | ••• | ••• |
| Company 5 | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, the global non invasive colon cancer screening market size was estimated at USD XX Million out of which North America held the major market of around 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.9% from 2024 to 2031. Sales of non-invasive colon cancer screening are poised to rise in North America due to factors such as increasing adoption of preventive healthcare practices, growing awareness about the benefits of early detection, and favourable reimbursement policies. Additionally, collaborations between healthcare providers and government agencies enhance accessibility to screening services, driving increased demand. In North America, the fecal immunochemical test (FIT) segment is expected to see significant growth, fuelled by its accuracy and ease of use, thereby further solidifying its market dominance in the region.
- According to Cognitive Market Research, The United States non-invasive colon cancer screening market had a market share of USD xx million in 2024 and is projected to grow at a CAGR of 2.7% during the forecast period. Sales of non-invasive colon cancer screening in the U.S. are expected to rise due to increasing awareness campaigns, favourable reimbursement policies, and a growing emphasis on preventive healthcare practices.
- Canada non-invasive colon cancer screening market had a market share of USD xx million in 2024 and is projected to grow at a CAGR of 3.7% during the forecast period. In Canada, sales of non-invasive colon cancer screening are poised to increase as a result of expanding healthcare infrastructure, rising public awareness about colorectal cancer, and government-supported screening programs.
- Mexico non-invasive colon cancer screening market had a market share of USD xx million in 2024 and is projected to grow at a CAGR of 3.4% during the forecast period.
The medical devices and consumables industry is growing rapidly, driven by aging populations, rising healthcare spending, and supportive regulations, boosting demand for implants, assistive tech, and home monitoring. Challenges include strict regulations, high R&D costs, and supply chain risks, but opportunities lie in emerging markets, health-tech partnerships, and eco-friendly devices. Key trends such as AI, precision medicine, and sustainable innovations are transforming healthcare and accelerating market growth.
Analyst Conclusion
- Author's Say's: North America held the major market of around 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.9% from 2024 to 2031.
- The sales of Fecal Immunochemical Test (FIT) are poised to rise due to its high accuracy, non-invasiveness, ease of use, and increasing awareness campaigns promoting colorectal cancer screening and early detection.
- Hospital sales are anticipated to surge owing to growing demand for comprehensive healthcare services, advancements in medical technology, increasing prevalence of chronic diseases, and expanding healthcare infrastructure.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
Frequently Asked Questions
★ Reviews
Rate this report
North America Non Invasive Colon Cancer Screening Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Type | Fecal Immunochemical Test FIT, Guaiac based Fecal Occult Blood Test gFOBT, Stool DNA Test |
|---|---|
| Application | Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Home Care Setting |
| List of Competitors | NOVIGENIX SA, EIKEN CHEMICAL CO. LTD., New Horizon, Clinical Genomics Technologies Pty Ltd., Exact Sciences Corporation, Epigenomics AG, bioMérieux Inc., Olympus Corporation, KARL STORZ SE & Co. KG, FUJIFILM Holdings America Corporation |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Top Players Ranking 2024
- 1.1.2 New Product Launch Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 NOVIGENIX SA
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 R&D Investment (Subject to data availability)
- 1.2.1.4 Financials (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.2 EIKEN CHEMICAL CO. LTD.
- 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.2.2 Business Overview
- 1.2.2.3 R&D Investment (Subject to data availability)
- 1.2.2.4 Financials (Subject to data availability)
- 1.2.2.5 Product Types Specification
- 1.2.2.6 Business Strategy
- 1.2.2.7 Recent Developments
- 1.2.2.8 Management Change
- 1.2.2.9 S.W.O.T Analysis
- 1.2.3 New Horizon
- 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.3.2 Business Overview
- 1.2.3.3 R&D Investment (Subject to data availability)
- 1.2.3.4 Financials (Subject to data availability)
- 1.2.3.5 Product Types Specification
- 1.2.3.6 Business Strategy
- 1.2.3.7 Recent Developments
- 1.2.3.8 Management Change
- 1.2.3.9 S.W.O.T Analysis
- 1.2.4 Clinical Genomics Technologies Pty Ltd.
- 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.4.2 Business Overview
- 1.2.4.3 R&D Investment (Subject to data availability)
- 1.2.4.4 Financials (Subject to data availability)
- 1.2.4.5 Product Types Specification
- 1.2.4.6 Business Strategy
- 1.2.4.7 Recent Developments
- 1.2.4.8 Management Change
- 1.2.4.9 S.W.O.T Analysis
- 1.2.5 Exact Sciences Corporation
- 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.5.2 Business Overview
- 1.2.5.3 R&D Investment (Subject to data availability)
- 1.2.5.4 Financials (Subject to data availability)
- 1.2.5.5 Product Types Specification
- 1.2.5.6 Business Strategy
- 1.2.5.7 Recent Developments
- 1.2.5.8 Management Change
- 1.2.5.9 S.W.O.T Analysis
- 1.2.6 Epigenomics AG
- 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.6.2 Business Overview
- 1.2.6.3 R&D Investment (Subject to data availability)
- 1.2.6.4 Financials (Subject to data availability)
- 1.2.6.5 Product Types Specification
- 1.2.6.6 Business Strategy
- 1.2.6.7 Recent Developments
- 1.2.6.8 Management Change
- 1.2.6.9 S.W.O.T Analysis
- 1.2.7 bioMérieux Inc.
- 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.7.2 Business Overview
- 1.2.7.3 R&D Investment (Subject to data availability)
- 1.2.7.4 Financials (Subject to data availability)
- 1.2.7.5 Product Types Specification
- 1.2.7.6 Business Strategy
- 1.2.7.7 Recent Developments
- 1.2.7.8 Management Change
- 1.2.7.9 S.W.O.T Analysis
- 1.2.8 Olympus Corporation
- 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.8.2 Business Overview
- 1.2.8.3 R&D Investment (Subject to data availability)
- 1.2.8.4 Financials (Subject to data availability)
- 1.2.8.5 Product Types Specification
- 1.2.8.6 Business Strategy
- 1.2.8.7 Recent Developments
- 1.2.8.8 Management Change
- 1.2.8.9 S.W.O.T Analysis
- 1.2.9 KARL STORZ SE & Co. KG
- 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.9.2 Business Overview
- 1.2.9.3 R&D Investment (Subject to data availability)
- 1.2.9.4 Financials (Subject to data availability)
- 1.2.9.5 Product Types Specification
- 1.2.9.6 Business Strategy
- 1.2.9.7 Recent Developments
- 1.2.9.8 Management Change
- 1.2.9.9 S.W.O.T Analysis
- 1.2.10 FUJIFILM Holdings America Corporation
- 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.10.2 Business Overview
- 1.2.10.3 R&D Investment (Subject to data availability)
- 1.2.10.4 Financials (Subject to data availability)
- 1.2.10.5 Product Types Specification
- 1.2.10.6 Business Strategy
- 1.2.10.7 Recent Developments
- 1.2.10.8 Management Change
- 1.2.10.9 S.W.O.T Analysis
- 1.2.1 NOVIGENIX SA
- 1.1 Top Competitors Analysis
Chapter 2. Global Non Invasive Colon Cancer Screening Market Analysis
- 2.1 Global Non Invasive Colon Cancer Screening Market Analysis
- 2.2 Global Non Invasive Colon Cancer Screening Market Analysis by Type
- 2.3 Global Non Invasive Colon Cancer Screening Market Analysis by Application
Chapter 3. North America Non Invasive Colon Cancer Screening Market Analysis
- 3.1 North America Non Invasive Colon Cancer Screening Market Analysis
- 3.2 North America Non Invasive Colon Cancer Screening Market Analysis by Country
- 3.3 North America Non Invasive Colon Cancer Screening Market Analysis by Type
- 3.4 North America Non Invasive Colon Cancer Screening Market Analysis by Application
- 3.5 North America Non Invasive Colon Cancer Screening Market Analysis by Key Players
Chapter 4. United States Non Invasive Colon Cancer Screening Market Analysis
- 4.1 United States Non Invasive Colon Cancer Screening Market Analysis
- 4.2 United States Non Invasive Colon Cancer Screening Market Analysis by Type
- 4.3 United States Non Invasive Colon Cancer Screening Market Analysis by Application
- 4.4 United States Non Invasive Colon Cancer Screening Market Analysis by Key Players
Chapter 5. Canada Non Invasive Colon Cancer Screening Market Analysis
- 5.1 Canada Non Invasive Colon Cancer Screening Market Analysis
- 5.2 Canada Non Invasive Colon Cancer Screening Market Analysis by Type
- 5.3 Canada Non Invasive Colon Cancer Screening Market Analysis by Application
- 5.4 Canada Non Invasive Colon Cancer Screening Market Analysis by Key Players
Chapter 6. Mexico Non Invasive Colon Cancer Screening Market Analysis
- 6.1 Mexico Non Invasive Colon Cancer Screening Market Analysis
- 6.2 Mexico Non Invasive Colon Cancer Screening Market Analysis by Type
- 6.3 Mexico Non Invasive Colon Cancer Screening Market Analysis by Application
- 6.4 Mexico Non Invasive Colon Cancer Screening Market Analysis by Key Players
Chapter 7. Type Analysis
- 7.1 Fecal Immunochemical Test FIT
- 7.2 Guaiac based Fecal Occult Blood Test gFOBT
- 7.3 Stool DNA Test
Chapter 8. Application Analysis
- 8.1 Hospitals
- 8.2 Speciality Clinics
- 8.3 Ambulatory Surgical Centers
- 8.4 Home Care Setting
Chapter 9. Qualitative Analysis (Subject to Data Availability)
- 9.1 Market Drivers
- 9.2 Market Restraints
- 9.3 Market Trends
- 9.4 Market Opportunity
- 9.5 Technological Road Map (Subject to Data Availability)
- 9.6 Product Life Cycle (Subject to Data Availability)
- 9.7 Customer and Buyer Behavior Analysis
- 9.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 9.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 9.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 9.7.4 Pricing, Affordability & Value Perception Analysis
- 9.7.5 Customer Segmentation & Demand Pattern Analysis
- 9.8 Industrial Chain Analysis (Subject to Data Availability)
- 9.8.1 Industry Chain Analysis
- 9.8.2 Manufacturing Cost Analysis
- 9.8.3 Supply Side Analysis
- 9.8.3.1 Raw Material Analysis
- 9.8.3.2 Raw Material Procurement Analysis
- 9.8.3.3 Raw Material Price Trend Analysis
- 9.9 PESTEL Analysis
- 9.9.1 Environmental Factors
- 9.9.2 Legal Factors
- 9.9.3 Technological Factors
- 9.9.4 Economic Factors
- 9.9.5 Political Factors
- 9.9.6 Social Factors
- 9.10 Porter’s Five Forces Analysis
- 9.10.1 Degree of Competition
- 9.10.2 Threat of Substitutes
- 9.10.3 Threat of New Entrants
- 9.10.4 Bargaining Power of Buyers
- 9.10.5 Bargaining Power of Suppliers
- 9.11 Patent Analysis (Subject to Data Availability)
- 9.12 ESG Analysis
- 9.13 Geopolitical Outlook
- 9.13.1 Global Power Realignment & Strategic Alliances
- 9.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 9.13.3 International Trade Relations & Market Access Environment
- 9.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 9.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 9.13.6 Technology Sovereignty & Digital Geopolitics
- 9.13.7 Strategic Implications for Investment, Growth & Market Entry
- 9.14 AI & Market Transformation
- 9.14.1 Competitive Landscape Disruption & Strategic Shifts
- 9.14.2 AI-Driven Transformation of Industry Value Chain
- 9.14.3 Evolution of Business Models & Revenue Streams
- 9.14.4 AI-Driven Product, Service & Innovation Transformation
- 9.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 10. Research Findings
- 10.1 Key Takeaways
- 10.2 Analyst Point of View
- 10.3 Assumptions and Acronyms
Chapter 11. Research Methodology and Sources
- 11.1 Primary Data Collection
- 11.1.1 Steps for Primary Data Collection
- 11.1.1.1 Identification of KOL
- 11.1.2 Backward Integration
- 11.1.3 Forward Integration
- 11.1.4 How Primary Research Help Us
- 11.1.5 Modes of Primary Research
- 11.1.1 Steps for Primary Data Collection
- 11.2 Secondary Research
- 11.2.1 How Secondary Research Help Us
- 11.2.2 Sources of Secondary Research
- 11.3 Data Validation
- 11.3.1 Data Triangulation
- 11.4 Data Representation
- 11.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the North America Non Invasive Colon Cancer Screening Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Medical Devices and Consumables Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the North America Non Invasive Colon Cancer Screening Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the north america non invasive colon cancer screening market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
